ELK GROVE VILLAGE, Ill., Oct. 3, 2024 /PRNewswire/ — Orsini, a leader in rare disease pharmacy solutions, is proud to announce the launch of ORBIT™ (Orsini Rare Business Intelligence Technology), an advanced artificial intelligence (AI)-enabled reporting and analytics platform designed to enhance patient care for those living with a rare disease. ORBIT leverages the power of AI to provide deeper insights and more personalized support, enabling pharmaceutical manufacturers to better understand and address the unique needs of rare disease patients. By harnessing the latest advancements in technology, ORBIT pairs real-world data collection with robust analytics and reporting capabilities to enable more informed decision-making and enhance patient engagement and adherence. ORBIT is designed for flexibility and agility, using an API-forward approach to exchange real-time data with our pharmacy, patient engagement platforms, manufacturers’ systems and other business associates as relevant.
“As the name suggests, ORBIT revolves around the patient, collecting and analyzing data to deliver a personalized experience,” said Ashok Singh, Chief Information Officer at Orsini. “This flexible, first-of-its-kind platform harnesses the power of AI to deliver better outcomes in rare disease care.”
In April, Orsini welcomed Singh to its executive management team. Singh is tasked with implementing technology enhancements aimed at driving innovation in rare disease patient care through AI-enabled technology. The debut of ORBIT is the first of several initiatives underway.
Visit orsinispecialtypharmacy.com/contact-us/ to request an ORBIT demo.
About Orsini
Providing patients with comprehensive and compassionate care since 1987, Orsini is a leader in rare diseases and gene therapies. Orsini partners with biopharma innovators, healthcare providers and payors to support patients and their families in accessing revolutionary treatments for rare diseases. Through integrated rare disease pharmacy solutions including pharmacy distribution, patient services, clinical management and convenient home infusion services, Orsini simplifies how patients connect to advanced therapies. Orsini’s high-touch care model centers on experienced and trained therapy care teams that provide personalized patient care to ensure that No Patient is Left Behind™.
Orsini holds accreditations with the Accreditation Commission for Health Care (ACHC), The Joint Commission, URAC and NABP. Orsini has earned URAC’s Rare Disease Pharmacy Center of Excellence Designation and ACHC’s Distinction in Rare Diseases and Orphan Drugs. For more information, connect with us at 847-734-7373 ext. 505, media@orsinihc.com, or www.orsini.com.
SOURCE Orsini
Black Book outlines an AI-era integrity architecture for healthcare benchmarking, instrumentation hardening, tiered verification, real-time…
Bagsværd, Denmark, 31 January 2026 – Thomas Rantzau, employee representative on the Board of Directors since…
Baltimore, Maryland, Jan. 31, 2026 (GLOBE NEWSWIRE) -- After sustaining water damage during the massive…
Science-Backed Spermidine Ritual Brings Cellular Renewal to a High-Performance Cultural Moment Primeadine Longevity Shot Primeadine…
CRANFORD, N.J., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (OTCQB: ENZN) (“Enzon” or…
MINNEAPOLIS, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Park Dental Partners, Inc. (NASDAQ: PARK), a leading…